Results 21 to 30 of about 20,487 (260)
Modeling SF-6D Health Utilities: Is Bayesian Approach Appropriate? [PDF]
Int J Environ Res Public Health, 2021 Background: Valuation studies of preference-based health measures like SF6D have been conducted in many countries. However, the cost of conducting such studies in countries with small populations or low- and middle-income countries (LMICs) can be prohibitive.
Kharroubi SA.
europepmc +6 more sources
The Importance of Accounting for Parameter Uncertainty in SF-6D Value Sets and Its Impact on Studies that Use the SF-6D to Measure Health Utility. [PDF]
Int J Environ Res Public Health, 2020 Background: The parameter uncertainty in the six-dimensional health state short form (SF-6D) value sets is commonly ignored. There are two sources of parameter uncertainty: uncertainty around the estimated regression coefficients and uncertainty around the model’s specification.
Kharroubi SA +3 more
europepmc +6 more sources
The Short Form 6 Dimensions (SF-6D): Development and Evolution. [PDF]
Appl Health Econ Health PolicyThis paper considers the development and evolution of the short-form 6 dimensions (SF-6D), a generic preference-weighted measure consisting of a health classification with accompanying value set that was developed from one of the widest used health related quality of life measures, the SF-36 health survey. This enabled health state utility values to be
Mukuria C +6 more
europepmc +3 more sources
Frontiers in Public Health, 2021 Objective: To compare the EuroQol-5D-3L (EQ-5D-3L) and the Short Form-6D (SF-6D) utility scores in family caregivers (FCs) of colorectal cancer (CRC) patients.Method: This study was performed on FCs of CRC patients from three primary cancer centers in ...
Cheng-yao Sun +7 more
doaj +1 more source
Exploring the Consistency of the SF-6D [PDF]
Value in Health, 2013 The six-dimensional health state short form (SF-6D) was designed to be derived from the short-form 36 health survey (SF-36). The purpose of this research was to compare the SF-6D index values generated from the SF-36 (SF-6DSF-36) with those obtained from the SF-6D administered as an independent instrument (SF-6DInd).
Ferreira, Lara Noronha +4 more
openaire +3 more sources
US valuation of the SF-6D. [PDF]
Med Decis Making, 2013 Background. The original SF-6D valuation study collected 3503 standard gambled responses from 611 UK respondents to predict quality-adjusted life year (QALY) values. Methods. Using 19,980 paired comparison responses from 666 US respondents and a stacked probit model, the 25 coefficients of the original SF-6D multiattribute utility (MAU) regression ...
Craig BM +3 more
europepmc +5 more sources
Unchained melody: revisiting the estimation of SF-6D values. [PDF]
Eur J Health Econ, 2016 In the original SF-6D valuation study, the analytical design inherited conventions that detrimentally affected its ability to predict values on a quality-adjusted life year (QALY) scale. Our objective is to estimate UK values for SF-6D states using the original data and multi-attribute utility (MAU) regression after addressing its limitations and to ...
Craig BM.
europepmc +4 more sources
Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary. [PDF]
PharmacoeconomicsThis study aimed to develop population norms for three preference-accompanied measures [EQ-5D-5L, Patient-Reported Outcomes Measurement Information System (PROMIS)-preference scoring system (PROPr) and Short-Form Six-Dimension (SF-6D)] in Hungary.In November 2020, an online cross-sectional survey was conducted among a representative sample of the ...
Nikl A +4 more
europepmc +5 more sources
Jurnal Manajemen dan Pelayanan Farmasi, 2020 The EuroQuality of life-5 dimension 5 level (EQ-5D-5L) and Short Form-6 Dimension (SF-6D) are the most widely used generic instruments for assessing utility as an outcome parameter in pharmacoeconomic studies.
Tri Murti Andayani +3 more
doaj +1 more source
A comparison between the EQ-5D and the SF-6D in patients with chronic obstructive pulmonary disease (COPD). [PDF]
PLoS ONE, 2014 The appropriate use of generic preference-based measures determines the accuracy of disease assessment and further decision on healthcare policy using quality adjusted life years.
Jing Chen +4 more
doaj +1 more source